Results 121 to 130 of about 165,216 (289)
CRISPR/Cas9, while transformative, faces challenges in specificity, precision, delivery, accessibility, flexibility, and safety. This review addresses these limitations by highlighting strategies to reduce off‐target effects, exploring HDR‐based and alternative editing approaches, and evaluating advanced delivery mechanisms.
Muna Alariqi+8 more
wiley +1 more source
Novel amides of mycophenolic acid and some heterocyclic derivatives as immunosuppressive agents. [PDF]
Walczak JM+6 more
europepmc +1 more source
IMMUNOSUPPRESSIVE AGENTS AND IMMUNE CYTOLYSIS IN VITRO
William U. Shipley
openalex +1 more source
Clinical Course of Patients with Ig A Nephropathy between Combined Treatment of Immunosuppressive Agents and ACE Inhibitor and ACE Inhibitor alone [PDF]
You‐Cheol Hwang+4 more
openalex +1 more source
Tumor‐Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune Evasion
This study identifies Globo H ceramide (GHCer) as a novel immune checkpoint molecule that suppresses the activation of conventional T lymphocytes while promoting the differentiation and function of regulatory T cells. The immunosuppressive effects of GHCer are mediated through the activation of the A2AR/cAMP/PKA pathway, which involves its interactions
Jing‐Yan Cheng+13 more
wiley +1 more source
Microsponge-derived mini tablets loaded with immunosuppressive agents: Pharmacokinetic investigation in human volunteers, cell viability and IVIVC correlation. [PDF]
Mehmood Y+5 more
europepmc +1 more source
A hollow nanomotor (PM‐HMSN/Arg) propelled by ultrasound‐triggered nitric oxide (NO) was developed. The nanomotor employs a “tethering‐relaxing‐drilling” mechanism to overcome biological barriers, enabling multimodal theranostics of cancer with deep penetration and extended lifetime.
Xue Xu+7 more
wiley +1 more source
Immunogenicity and safety of SARS-CoV-2 vaccine with immunosuppressive agents. [PDF]
Kamei K+7 more
europepmc +1 more source
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan+6 more
wiley +1 more source